Literature DB >> 18057530

Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients.

Merete Lund Hetland1, Ib Jarle Christensen, Tine Lottenburger, Julia Sidenius Johansen, Mads Nordahl Svendsen, Kim Hørslev-Petersen, Lone Nielsen, Hans Jørgen Nielsen.   

Abstract

BACKGROUND: Soluble vascular endothelial growth factor (VEGF) is a promising biomarker in monitoring rheumatoid arthritis (RA), but studies of pre-analytical and biologic variability are few.
METHODS: VEGF was measured by ELISA methods in serum and plasma from healthy persons and RA patients. Pre-analytical factors were investigated. A reference interval for VEGF was established in serum and plasma from 306 healthy persons. Diurnal, day-to-day, week-to-week, long-term variability, and impact of exercise were evaluated.
RESULTS: Delayed processing time, room temperature, low centrifugal force and contamination of plasma with cellular elements lead to significant increases in VEGF levels, whereas storage for up to 2 years at -80 degrees C or up to 10 freeze/thaw cycles did not affect VEGF levels. Serum VEGF levels were 7-10 fold higher than plasma VEGF levels. Reference intervals for VEGF (plasma: 45 pg/ml (range: non-detectable to 352); serum: 328 pg/ml (53-1791)) were independent of gender and age. Short- and long-term biologic variability included diurnal variation (sampling should take place after 7 AM) and impact of exercise (increased VEGF immediately after bicycling normalised within 1 hour).
CONCLUSIONS: Pre-analytical factors and biologic variability including diurnal variation and impact of exercise should be accounted for in future studies that include circulating VEGF as a biological marker.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18057530      PMCID: PMC3850601          DOI: 10.1155/2008/707864

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  21 in total

1.  VEGF/VEGFR-2 changes in frontal cortex, choroid plexus, and CSF after chronic obstructive hydrocephalus.

Authors:  Jun Yang; Stephen M Dombrowski; Abhishek Deshpande; Natalie Krajcir; Mark G Luciano
Journal:  J Neurol Sci       Date:  2010-09-15       Impact factor: 3.181

Review 2.  Banking of biological fluids for studies of disease-associated protein biomarkers.

Authors:  Anne-Sofie Schrohl; Sidse Würtz; Elise Kohn; Rosamonde E Banks; Hans Jørgen Nielsen; Fred C G J Sweep; Nils Brünner
Journal:  Mol Cell Proteomics       Date:  2008-08-01       Impact factor: 5.911

3.  Monocyte chemotactic protein-1 (MCP-1) and growth factors called into question as markers of prolonged psychosocial stress.

Authors:  Ingibjörg H Jonsdottir; Daniel A Hägg; Kristina Glise; Rolf Ekman
Journal:  PLoS One       Date:  2009-11-03       Impact factor: 3.240

Review 4.  Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.

Authors:  Lokesh Agrawal; Kelly B Engel; Sarah R Greytak; Helen M Moore
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

Review 5.  Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output.

Authors:  Giovanni Lombardi; Veronica Sansoni; Giuseppe Banfi
Journal:  Ann Transl Med       Date:  2017-08

6.  Pomegranate extract alleviates disease activity and some blood biomarkers of inflammation and oxidative stress in Rheumatoid Arthritis patients.

Authors:  M Ghavipour; G Sotoudeh; E Tavakoli; K Mowla; J Hasanzadeh; Z Mazloom
Journal:  Eur J Clin Nutr       Date:  2016-08-31       Impact factor: 4.016

Review 7.  The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings.

Authors:  Maryam Shabihkhani; Gregory M Lucey; Bowen Wei; Sergey Mareninov; Jerry J Lou; Harry V Vinters; Elyse J Singer; Timothy F Cloughesy; William H Yong
Journal:  Clin Biochem       Date:  2014-01-12       Impact factor: 3.281

Review 8.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.

Authors:  Vasiliki Thomeas; Selina Chow; Jose O Gutierrez; Sanja Karovic; Kristen Wroblewski; Emily Kistner-Griffin; Theodore G Karrison; Michael L Maitland
Journal:  J Clin Pharmacol       Date:  2014-01-17       Impact factor: 3.126

10.  Novel biochemical markers of psychosocial stress in women.

Authors:  Marie Asberg; Ake Nygren; Rosario Leopardi; Gunnar Rylander; Ulla Peterson; Lukas Wilczek; Håkan Källmén; Mirjam Ekstedt; Torbjörn Akerstedt; Mats Lekander; Rolf Ekman
Journal:  PLoS One       Date:  2009-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.